AU2003213956A1 - Improved hormone replacement therapy - Google Patents
Improved hormone replacement therapyInfo
- Publication number
- AU2003213956A1 AU2003213956A1 AU2003213956A AU2003213956A AU2003213956A1 AU 2003213956 A1 AU2003213956 A1 AU 2003213956A1 AU 2003213956 A AU2003213956 A AU 2003213956A AU 2003213956 A AU2003213956 A AU 2003213956A AU 2003213956 A1 AU2003213956 A1 AU 2003213956A1
- Authority
- AU
- Australia
- Prior art keywords
- replacement therapy
- hormone replacement
- improved
- improved hormone
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36970702P | 2002-04-03 | 2002-04-03 | |
US36962902P | 2002-04-03 | 2002-04-03 | |
US60/369,707 | 2002-04-03 | ||
US60/369,629 | 2002-04-03 | ||
PCT/CA2003/000491 WO2003082299A1 (en) | 2002-04-03 | 2003-04-03 | Improved hormone replacement therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003213956A1 true AU2003213956A1 (en) | 2003-10-13 |
Family
ID=28678278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003213956A Abandoned AU2003213956A1 (en) | 2002-04-03 | 2003-04-03 | Improved hormone replacement therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003213956A1 (en) |
WO (1) | WO2003082299A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
EP1635843B1 (en) * | 2003-06-25 | 2009-01-07 | Bayer Schering Pharma Aktiengesellschaft | Therapy comprising dienogest for hormone replacement and depression |
WO2007076144A2 (en) * | 2005-12-27 | 2007-07-05 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US10864220B2 (en) | 2015-06-30 | 2020-12-15 | Shanghai Jiao Tong University | Applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
CA2267743C (en) * | 1999-03-30 | 2011-07-26 | Robert F. Casper | Low dose estrogen interrupted hormone replacement therapy |
AU5181200A (en) * | 1999-06-04 | 2000-12-28 | General Hospital Corporation, The | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
WO2002074315A1 (en) * | 2001-03-21 | 2002-09-26 | Schering Aktiengesellschaft | Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy |
-
2003
- 2003-04-03 WO PCT/CA2003/000491 patent/WO2003082299A1/en not_active Application Discontinuation
- 2003-04-03 AU AU2003213956A patent/AU2003213956A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003082299A1 (en) | 2003-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003288586A1 (en) | Electrode arrangement | |
AU2003224654A1 (en) | Photodynamic therapy for pre-melanomas | |
AU2003260760A1 (en) | Implantable replacement joint | |
AU2003276447A1 (en) | Inhalers | |
AU2003215209A1 (en) | Syringe | |
ZA200308027B (en) | Hormone replacement therapy | |
AU2003296895A1 (en) | Combination therapy for controlling appetites | |
AU2003209226A1 (en) | Adiponectin gene therapy | |
AU2002951082A0 (en) | Therapeutic cellular agents | |
AU2003279911A1 (en) | Therapeutic formulations | |
AU2003289742A1 (en) | Stable therapeutic proteins | |
AU2003259457A1 (en) | Auto-destructible syringe | |
AUPS160602A0 (en) | Therapeutic method | |
AU2003247005A1 (en) | Therapy combination | |
AU2003233357A1 (en) | Dressing aid | |
AU2003201065A1 (en) | Diamond electrode | |
AU2003249722A1 (en) | Therapeutic amides | |
AU2003245794A1 (en) | Glycosaminoglycan-dnase combination therapy | |
AU2003215150A1 (en) | Therapeutic compounds | |
AU2003228198A1 (en) | Av-fistula bandage | |
AU2003282722A1 (en) | Therapeutic compositions | |
AU2003297657A1 (en) | Antifungal therapeutic agents | |
AU2003255727A1 (en) | Syringes | |
AU2003213956A1 (en) | Improved hormone replacement therapy | |
AU2002952559A0 (en) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |